RAP-219
RAP-219-FOS-302
Phase 3 small_molecule active
Quick answer
RAP-219 for Focal Seizure is a Phase 3 program (small_molecule) at Rapport Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Rapport Therapeutics
- Indication
- Focal Seizure
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active